NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
基本信息
- 批准号:6374990
- 负责人:
- 金额:$ 21.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-09-30 至 2005-08-31
- 项目状态:已结题
- 来源:
- 关键词:CD14 molecule RNase protection assay bone metabolism disorder cell differentiation chickens confocal scanning microscopy gel mobility shift assay glucocorticoids in situ hybridization interleukin 1 isozymes laboratory mouse molecular cloning nitric oxide nitric oxide synthase northern blottings nucleic acid sequence osteoclasts pathologic bone resorption polymerase chain reaction
项目摘要
DESCRIPTION (Verbatim from the Applicant): Bone remodeling is a sensitively
regulated dynamic process in which bone resorption by multinucleated
osteoclasts (OCs) is normally closely followed by osteoblast (OB)-mediated bone
formation. The multifunctional signal molecule, nitric oxide (NO), serves as an
important intercellular autocrine and paracrine signal modulator in normal, as
well as in pathological bone modeling and remodeling processes, and NO appears
to exert profound effects on OB proliferation/survival, OC development and
function. NO is formed from L-arginine in an oxidative reaction catalyzed by NO
synthase (NOS) isoenzymes that are either constitutively expressed and
calcium-activated (endothelial eNOS and neuronal nNOS isoforms), or
transcriptionally induced (inducible NOS isoform) in response to inflammatory
stimuli. Elevated NO levels potently inhibit bone resorption, both in vitro and
in vivo, and NO actions on OCs, like other cells, involves a cGMP-dependent
mechanism. The possible autocrine effect of NO on OCs has also begun to be
examined, since it is now well established that OCs express both iNOS and eNOS.
Although avian OCs express both iNOS messenger RNA (mRNA) and protein,
inflammatory cytokines or LPS do not induce iNOS mRNA or protein in authentic
mature Ocs, whereas elevated levels of calcium do. In contrast to Ocs, LPS and
inflammatory cytokines induce iNOS and NO in many other cell types, including
avian non-resorptive marrow-derived giant cells (MAGC). Therefore, we
hypothesize that as OCs differentiate into fully functional resorption
competent cells, the regulation of INOS expression is modified and this change
in iNOS regulation impacts on OC-function in normal, as well as pathological OC
function. The goal of this revised renewal application is to begin to
understand the cell and molecular mechanisms involved in this unique OC iNOS
regulation. The following Specific Aims are proposed: (1) to determine if the
change in cytokine- and LPS-mediated OC iNOS regulation is a consequence of
alterations in signaling pathways during the process of OC differentiation. As
part of this aim, we will compare chicken, mouse, and human OC developmental
models; (2) to identify promoter regulatory sequences and transcription factors
that mediate (a) the differential induction of iNOS gene by calcium, PMA and
inflammatory agents in MAGCs compared to mature resorbing OC, and (b) the
inhibition of inflammatory-mediated iNOS gene induction following attachment of
MAGCs to mineralized bone matrices; and (3) to analyze the signaling mechanisms
by which NO alters OC activity. Such studies are anticipated to reveal new
aspects of normal bone remodeling mechanisms and have potential to lend insight
into skeletal pathologies such as implant loosening, osteoarthritis, other
inflammatory skeletal disorders, and osteoporosis.
描述(来自申请人):骨重塑是一种敏感的
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Philip A Osdoby其他文献
Philip A Osdoby的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Philip A Osdoby', 18)}}的其他基金
OSTEOGENESIS IMPERFECTA, AND NITRIC OXIDE THERAPY
成骨不全和一氧化氮疗法
- 批准号:
7318366 - 财政年份:2007
- 资助金额:
$ 21.71万 - 项目类别:
OSTEOGENESIS IMPERFECTA, AND NITRIC OXIDE THERAPY
成骨不全和一氧化氮疗法
- 批准号:
7477733 - 财政年份:2007
- 资助金额:
$ 21.71万 - 项目类别:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
- 批准号:
6652038 - 财政年份:2000
- 资助金额:
$ 21.71万 - 项目类别:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
- 批准号:
6534426 - 财政年份:2000
- 资助金额:
$ 21.71万 - 项目类别:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
- 批准号:
6287613 - 财政年份:2000
- 资助金额:
$ 21.71万 - 项目类别:
NITRIC OXIDE, OSTEOCLASTS AND METABOLIC BONE DISEASE
一氧化氮、破骨细胞和代谢性骨疾病
- 批准号:
6796894 - 财政年份:2000
- 资助金额:
$ 21.71万 - 项目类别:
相似海外基金
NOVEL RNASE PROTECTION ASSAY FOR CYTOKINE MRNAS
细胞因子 MRNAS 的新型 RNA 酶保护测定
- 批准号:
6317727 - 财政年份:2000
- 资助金额:
$ 21.71万 - 项目类别:














{{item.name}}会员




